Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy

Allison Ross, Corrilynn Hileman, Todd Brown, Neal Fedarko, Norma Storer, Danielle Labbato, Grace McComsey

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Objectives: Thiazoledinediones increase limb fat in HIV+ patients with lipoatrophy. However, their use in the general population has been associated with bone loss and fracture. We sought to determine the effects of rosiglitazone on bone metabolism in HIV-infected patients. Methods: HIV+ patients with lipoatrophy were randomized to rosiglitazone versus placebo for 48 weeks in a double-blind, placebo-controlled trial. Limb fat, bone mineral density (BMD), bone formation markers (procollagen type 1 amino-terminal propeptide [P1NP], osteocalcin [OC]) and bone resorption markers (C-terminal telopeptide of type I collagen [CTX]) were measured, along with receptor activator for nuclear factor kappa β ligand (RANKL), osteoprotegerin (OPG), and inflammatory cytokines. Results: Seventy-one subjects were randomized to rosiglitazone or placebo: 17% female and 51% white. Total BMD did not change significantly in either group. In the rosiglitazone group, P1NP showed statistically significant decreases at 24 and 48 weeks; however, changes compared to placebo were only significant at 24 weeks. OC decreased significantly in the rosiglitazone group at 24 weeks, but there were no between-group differences. CTX, RANKL, or OPG did not change for either group. Multivariable regression within the rosiglitazone arm showed P1NP changes were inversely associated with limb fat changes, protease inhibitors, and tenofovir use. Conclusion: Rosiglitazone use was associated with decreased bone formation, but it did not alter bone resorption or total BMD. The increase in limb fat that accompanies rosiglitazone use appears to be associated with decreased osteoblast activity. Further studies are needed to determine the effect of thiazoledinediones on bone health in HIV-infected persons.

Original languageEnglish (US)
Pages (from-to)212-221
Number of pages10
JournalHIV Clinical Trials
Issue number4
StatePublished - Jan 1 2012


  • HIV
  • bone mineral density
  • bone turnover markers
  • rosiglitazone
  • thiazoledinediones

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy'. Together they form a unique fingerprint.

Cite this